Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10989617 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1402391 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL11410844 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL6741884 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1402315 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2556965 | 1.00 | NR5A1 (0.66) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2091080 | 0.98 | NR5A1 (0.62) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10528088 | 0.94 | RARB (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10528469 | 0.94 | RARB (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10525853 | 0.94 | RARB (0.61) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | claimed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | claimed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | claimed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | claimed |
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2022-12-08 | — | — | US | disclosed |
| EP-4065095-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021105435-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (DE) | 2021-06-03 | — | — | WO | disclosed |
| EP-3827816-A1 | PROOXIDATIVE CHAIN-TRANSFER AGENTS FOR USE IN THE TREATMENT OF MALIGNANT TUMOUR OR INFECTIOUS DISEASES | Universitätsmedizin der Johannes Gutenberg-Universität Mainz (DE) | 2021-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387369-A1 | Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases | SLC25A1, SLC19A2, SLC25A21 | NR5A1 2276/4885LTA4H 419/4885TP53 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.